Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of coadministration of RSVPreF3 OA vaccine with Fluad Tetra in adults aged 65 years and older
2022-000623-21Phase 3Active
- Sponsor
- GSK
- Start
- Jul 2022
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in respiratory syncytial virus disease (RSV) and influenza comparing RSVPreF3 OA + Fluad Tetra coadministration with Fluad Tetra alone (2 arms). Primary endpoint: Hemagglutination inhibition antibody titers. Started Jul 2022; status: active.
02
Drugs
GSK3003899Ainfluenza virus type B (Victoria)
03
Conditions
respiratory syncytial virus disease (RSV)influenza
Beyond the preview
Go deeper on 2022-000623-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000623-21.